12:00 AM
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Margetuximab: Phase II started

MacroGenics began an open-label, U.S. Phase II trial to evaluate IV margetuximab in up to 41 patients.

MacroGenics Inc., Rockville,...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >